Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
DMRA
SELLDamora Therapeutics, Inc. · Healthcare · United States · $1.6B · Avg Vol: $24M/d
COMPANY DESCRIPTION
Damora Therapeutics, Inc. is a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for treating various diseases. Its competitive strength derives from its proprietary scientific platforms, intellectual property portfolio, and specialized research capabilities. As a clinical-stage biotech firm, its value is significantly tied to the progress and successful outcomes of its drug pipeline through clinical trials and regulatory approvals.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -1.01 | -0.64 | -0.40 | -0.10 | — | -2.99 | -1.75 | -2.08 | — |
| Shares | 61.6M | 61.6M | 61.6M | 61.6M | 0.0% | 61.6M | — | — | — |
| Debt | 0.8M | 0.2M | 73.0K | 68.0K | -56.1% | — | — | — | — |
| Equity | 61.8M | 32.3M | 15.8M | 240.4M | 57.3% | — | — | — | — |
| Op CF | -42.9M | -36.9M | -18.6M | -6.7M | — | -24.9M | — | — | — |
| Inv CF | 12.4M | 22.3M | 11.7M | -17.4M | — | — | — | — | — |
| Fin CF | 0.5M | 2.9M | 0 | 266.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DMRA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| DMRA | Damora Therapeutics, Inc.(you) | $1.6B | 27 | SELL |
| ARDX | Ardelyx, Inc. | $1.5B | 27 | SELL |
| AVBP | ArriVent BioPharma, Inc. | $1.6B | 29 | SELL |
| ABSI | Absci Corporation | $1.8B | 27 | SELL |
| TYRA | Tyra Biosciences, Inc. | $1.9B | 26 | SELL |
| SION | Sionna Therapeutics, Inc. | $1.9B | 28 | SELL |
| MNKD | MannKind Corporation | $1.3B | 28 | SELL |
| RAPP | Rapport Therapeutics, Inc. | $1.9B | 29 | SELL |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.9B | 29 | SELL |
| ZYME | Zymeworks Inc. | $1.8B | 22 | SELL |
Peer medians: ROE -21.2% · P/E 27.1x · Gross margin 44.5%